ESMO 2023 BioNTech Data

BNT211: First-in-Class Approach for CLDN6+ Solid Tumors CLDN6 CART +1 CLDN6 CARVac αCLDN6 scvf CD8 hinge 4-1BB CD33 Highly sensitive and specific 2nd-generation CAR against CLDN6 CLDN6 is absent from healthy adult tissue, but expressed in a variety of cancers1 Clinically proven RNA-lipoplex vaccine for body-wide delivery of antigens to dendritic cells 1,2 Amplification and persistence of CAR-T cells by repeat administration 3 Full-length CLDN6 RNA Liposomes CLDN6 Claudin 6; CAR = chimeric antigen receptor. BIONTECH

View entire presentation